Dr. Patrick M. Moriarty, M.D.
Clinical Pharmacology (Clinical Pharmacology Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 80
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Pharmacology Physician primary
KS license 04-25361 -
Internal Medicine Physician
KS license 04-25361
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- St Lukes Hospital of Kansas City Kansas City, MO
- Nkc Health North Kansas City, MO
- Lmh Lawrence, KS
- Neosho Memorial Regional Medical Center Chanute, KS
Medical groups
- Kansas University Physicians Inc (1,849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 97
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Telephone medical discussion with physician, 21-30 minutes | 47 | 47 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Repatha Sureclick (evolocumab) Other prescribers in Kansas City, KS | 1,134 |
| Ezetimibe Other prescribers in Kansas City, KS | 490 |
| Rosuvastatin Calcium Other prescribers in Kansas City, KS | 485 |
| Praluent Pen (alirocumab) Other prescribers in Kansas City, KS | 447 |
| Vascepa (icosapent ethyl) Other prescribers in Kansas City, KS | 272 |
| Icosapent Ethyl Other prescribers in Kansas City, KS | 105 |
| Atorvastatin Calcium Other prescribers in Kansas City, KS | 93 |
| Allopurinol Other prescribers in Kansas City, KS | 85 |
| Metformin Hcl Other prescribers in Kansas City, KS | 84 |
| Carvedilol Other prescribers in Kansas City, KS | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $73,019 in total to this clinician.
| Kaneka Medical America LLC | $73,019 |
|---|
| Consulting Fee | $73,019 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kaneka Medical America LLC Nov 19, 2025 | Consulting Fee Apheresis Machine · Nephrology | $73,019 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $272,206 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Dis…
Novartis Pharmaceuticals Corporation - Study name not reported
Ionis Pharmaceuticals, Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - Study name not reported
Ionis Pharmaceuticals, Inc. - MEASuRE: Metreleptin Effectiveness And Safety Registry
Chiesi USA, Inc. · Recruiting · NCT02325674
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.